{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Grohskopf_et_al.__2023_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 3
  },
  "completeness_stats": {
    "existing_evidence": 3,
    "new_evidence_found": 3,
    "total_evidence": 6
  },
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines).",
      "supports_claim": true,
      "explanation": "The quote appears on page 9 of the document: 'Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines).' The numbers and technical content match the quote to verify.. The quote directly supports the claim that Flublok (RIV4) contains 45 \u00b5g of HA per virus, which is 3 times the 15 \u00b5g per virus in standard-dose flu vaccines. This substantiates the first part of the claim about antigen content. The quote does not explicitly mention immunogenicity, but the claim's main factual assertion about antigen content is fully supported by the quote as found in the document.",
      "presence_explanation": "The quote appears on page 9 of the document: 'Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines).' The numbers and technical content match the quote to verify.",
      "support_explanation": "The quote directly supports the claim that Flublok (RIV4) contains 45 \u00b5g of HA per virus, which is 3 times the 15 \u00b5g per virus in standard-dose flu vaccines. This substantiates the first part of the claim about antigen content. The quote does not explicitly mention immunogenicity, but the claim's main factual assertion about antigen content is fully supported by the quote as found in the document.",
      "original_relevance": "This quote explicitly states that Flublok (RIV4) contains 45 \u00b5g of HA per virus, which is 3 times the 15 \u00b5g per virus in standard-dose flu vaccines, directly supporting the claim about antigen content."
    },
    {
      "id": 3,
      "quote": "Two of these vaccines, HD-IIV and RIV, are higher dose vaccines, which contain an increased dose of HA antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines). The adjuvanted vaccine contains 15 \u00b5g of HA per virus, similarly to nonadjuvanted SD-IIVs, but contains the adjuvant MF59. HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, with the most evidence available for HD-IIV3.",
      "supports_claim": true,
      "explanation": "The quote appears on page 14 of the document, with only minor differences in wording and formatting. The content is semantically equivalent: 'Two of these vaccines, HD-IIV and RIV, are higher dose vaccines, which contain an increased dose of HA antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines). The adjuvanted vaccine contains 15 \u00b5g of HA per virus, similarly to nonadjuvanted SD-IIVs, but contains the adjuvant MF59. HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, with the most evidence available for HD-IIV3.' This matches the quote to verify, with only minor formatting differences (e.g., 'nonadjuvanted' vs 'non adjuvant ed'). All facts, numbers, and technical content are preserved.. The quote directly supports the claim. It states that RIV4 (Flublok) contains 45 \u00b5g of HA antigen per virus, which is 3 times the 15 \u00b5g in standard-dose inactivated vaccines. It also notes that HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, which is a direct reference to greater immunogenicity or effectiveness. Thus, the quote both confirms the 3x antigen content and links this higher dose to greater immunogenicity/benefit versus standard-dose flu vaccines.",
      "presence_explanation": "The quote appears on page 14 of the document, with only minor differences in wording and formatting. The content is semantically equivalent: 'Two of these vaccines, HD-IIV and RIV, are higher dose vaccines, which contain an increased dose of HA antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines). The adjuvanted vaccine contains 15 \u00b5g of HA per virus, similarly to nonadjuvanted SD-IIVs, but contains the adjuvant MF59. HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, with the most evidence available for HD-IIV3.' This matches the quote to verify, with only minor formatting differences (e.g., 'nonadjuvanted' vs 'non adjuvant ed'). All facts, numbers, and technical content are preserved.",
      "support_explanation": "The quote directly supports the claim. It states that RIV4 (Flublok) contains 45 \u00b5g of HA antigen per virus, which is 3 times the 15 \u00b5g in standard-dose inactivated vaccines. It also notes that HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, which is a direct reference to greater immunogenicity or effectiveness. Thus, the quote both confirms the 3x antigen content and links this higher dose to greater immunogenicity/benefit versus standard-dose flu vaccines.",
      "original_relevance": "This quote reiterates the 3x HA antigen content in Flublok (RIV4) compared to standard-dose vaccines and notes that this higher dose has been linked to greater immunogenicity in some studies."
    },
    {
      "id": 4,
      "quote": "A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).",
      "supports_claim": true,
      "explanation": "The quote 'A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).' appears on page 21 of the document in the section describing Flublok Quadrivalent (RIV4): 'Dosage and Administration: RIV4 is administered by IM injection via needle and syringe. A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).' The content, numbers, and meaning are identical to the quote provided.. The quote directly supports the first part of the claim by stating that Flublok (RIV4) contains 45 \u00b5g of HA per virus in a 0.5-mL dose. Elsewhere in the document (e.g., page 19), it is stated that standard-dose flu vaccines contain 15 \u00b5g of HA per virus per dose. This means Flublok contains 3 times the HA antigen per virus compared to standard-dose vaccines, as claimed. The quote does not itself address immunogenicity, but the claim's first part (antigen content) is fully substantiated by the quote and the document's explicit comparison.",
      "presence_explanation": "The quote 'A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).' appears on page 21 of the document in the section describing Flublok Quadrivalent (RIV4): 'Dosage and Administration: RIV4 is administered by IM injection via needle and syringe. A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).' The content, numbers, and meaning are identical to the quote provided.",
      "support_explanation": "The quote directly supports the first part of the claim by stating that Flublok (RIV4) contains 45 \u00b5g of HA per virus in a 0.5-mL dose. Elsewhere in the document (e.g., page 19), it is stated that standard-dose flu vaccines contain 15 \u00b5g of HA per virus per dose. This means Flublok contains 3 times the HA antigen per virus compared to standard-dose vaccines, as claimed. The quote does not itself address immunogenicity, but the claim's first part (antigen content) is fully substantiated by the quote and the document's explicit comparison.",
      "original_relevance": "This quote from the section on Flublok (RIV4) confirms the per-virus HA content, supporting the claim that Flublok contains 3x the HA antigen of standard-dose flu vaccines."
    }
  ],
  "new_evidence": [
    {
      "id": "comp_1",
      "quote": "Quad rival ent Recombinant Influenza Vaccine (RIV4) Available Vaccine. One recombinant influenza vaccine, Flublok Quad rival ent (RIV4), is expected to be available during the 2022-23 influenza season. RIV4 is approved for persons aged \u226518 years. This vaccine contains recombinant HA produced in an insect cell line using genetic sequences from cell derived influenza viruses and is manufactured without the use of influenza viruses or eggs (127). Dosage and Administration: RIV4 is administered by IM injection via needle and syringe. A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).",
      "relevance_explanation": "This quote explicitly states that Flublok (RIV4) contains 45 \u00b5g of HA per virus per dose, which is three times the 15 \u00b5g per virus found in standard-dose flu vaccines, directly supporting the claim about antigen content.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Standard dose, nonadjuvanted IIV4 s contain 15 \u00b5g of HA per vaccine virus in a 0.5-mL dose (7.5 \u00b5g of HA per vaccine virus in a 0.25-mL dose). For 2022-23, this category is expected to include five different vaccines (Table 1).",
      "relevance_explanation": "This quote provides the HA content for standard-dose flu vaccines (15 \u00b5g per virus), which is necessary for comparison to Flublok's 45 \u00b5g per virus, supporting the '3x' claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "Two of these vaccines, HD-IIV and RIV, are higher dose vaccines, which contain an increased dose of HA antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines). The adjuvanted vaccine contains 15 \u00b5g of HA per virus, similarly to nonadjuvanted SD-IIVs, but contains the adjuvant MF59. HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, with the most evidence available for HD-IIV3.",
      "relevance_explanation": "This quote not only reiterates the 3x HA content of Flublok (RIV4) compared to standard-dose vaccines, but also states that higher dose vaccines like RIV have shown relative benefit (greater immunogenicity) compared with standard-dose vaccines in certain studies, directly supporting both parts of the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "model_used": "gpt-4.1"
}